Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia

Young Mi Han, Hyun Joo Seo, Seo Heui Choi, Yu Jin Jung, So Yoon Ahn, Hye Soo Yoo, Se In Sung, Jae Won Shim, Yeon Kyung Lee, Sun Young Ko, Son Moon Shin, Jong Hee Hwang, Jang Hoon Lee, Byung Min Choi, Eun Sun Kim, Ji Hyun Jeon, Sung Shin Kim, Yun Sil Chang, Won Soon Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to observe the effects of prophylactic palivizumab on hospitalization secondary to respiratory syncytial virus (RSV) infection (RSVhospitalization) in former very low birth weight infants (VLBWI) with bronchopulmonary dysplasia (BPD). This study also sought to identify the risk factors of RSVhospitalizationin this particular infant population. A prospective observational study was conducted between September 2007 and April 2008 in seven Korean hospitals. Children with a history of very low birth weight, a diagnosis of BPD and who were <2 yr old at the onset of the RSV season were included in this study. Palivizumab injections were administered monthly for a maximum of five months during the RSV season. RSVhospitalization rates were reviewed, and RSVhospitalization rates between subgroups were categorized by gestational age, birth weight, and duration of ventilator care. A total of 90 subjects completed the follow-up interviews. The mean gestational age at birth was 26.1±1.7 weeks, and the mean birth weight was 889.4±222.2 g. The incidence of RSVhospitalization in the study population was 8.9% (8/90), and the mean hospital stay was 11.0±5.5 days, including one death. There were no statistically significant differences in the patients' demographic characteristics or risk factors for RSV hospitalization. When subgroup analyses were conducted, there were still no statistically significant differences. The administration of palivizumab prophylaxis during the entire RSV season is important in VLBWI with BPD, regardless of their gestational age and birth weight, or previous ventilator dependency.

Original languageEnglish
Pages (from-to)924-931
Number of pages8
JournalJournal of Korean Medical Science
Volume30
Issue number7
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Respiratory Syncytial Virus Infections
Bronchopulmonary Dysplasia
Very Low Birth Weight Infant
Respiratory Syncytial Viruses
Birth Weight
Gestational Age
Mechanical Ventilators
Hospitalization
Population
Observational Studies
Length of Stay
Demography
Parturition
Prospective Studies
Interviews
Injections
Palivizumab
Incidence

Keywords

  • Bronchopulmonary dysplasia
  • Hospitalization
  • Infant
  • Palivizumab
  • Preterm
  • Respiratory syncytial viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia. / Han, Young Mi; Seo, Hyun Joo; Choi, Seo Heui; Jung, Yu Jin; Ahn, So Yoon; Yoo, Hye Soo; Sung, Se In; Shim, Jae Won; Lee, Yeon Kyung; Ko, Sun Young; Shin, Son Moon; Hwang, Jong Hee; Lee, Jang Hoon; Choi, Byung Min; Kim, Eun Sun; Jeon, Ji Hyun; Kim, Sung Shin; Chang, Yun Sil; Park, Won Soon.

In: Journal of Korean Medical Science, Vol. 30, No. 7, 01.01.2015, p. 924-931.

Research output: Contribution to journalArticle

Han, YM, Seo, HJ, Choi, SH, Jung, YJ, Ahn, SY, Yoo, HS, Sung, SI, Shim, JW, Lee, YK, Ko, SY, Shin, SM, Hwang, JH, Lee, JH, Choi, BM, Kim, ES, Jeon, JH, Kim, SS, Chang, YS & Park, WS 2015, 'Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia', Journal of Korean Medical Science, vol. 30, no. 7, pp. 924-931. https://doi.org/10.3346/jkms.2015.30.7.924
Han, Young Mi ; Seo, Hyun Joo ; Choi, Seo Heui ; Jung, Yu Jin ; Ahn, So Yoon ; Yoo, Hye Soo ; Sung, Se In ; Shim, Jae Won ; Lee, Yeon Kyung ; Ko, Sun Young ; Shin, Son Moon ; Hwang, Jong Hee ; Lee, Jang Hoon ; Choi, Byung Min ; Kim, Eun Sun ; Jeon, Ji Hyun ; Kim, Sung Shin ; Chang, Yun Sil ; Park, Won Soon. / Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia. In: Journal of Korean Medical Science. 2015 ; Vol. 30, No. 7. pp. 924-931.
@article{677e77fbde2d4dd08e5a6b14fcc3b072,
title = "Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia",
abstract = "The aim of this study was to observe the effects of prophylactic palivizumab on hospitalization secondary to respiratory syncytial virus (RSV) infection (RSVhospitalization) in former very low birth weight infants (VLBWI) with bronchopulmonary dysplasia (BPD). This study also sought to identify the risk factors of RSVhospitalizationin this particular infant population. A prospective observational study was conducted between September 2007 and April 2008 in seven Korean hospitals. Children with a history of very low birth weight, a diagnosis of BPD and who were <2 yr old at the onset of the RSV season were included in this study. Palivizumab injections were administered monthly for a maximum of five months during the RSV season. RSVhospitalization rates were reviewed, and RSVhospitalization rates between subgroups were categorized by gestational age, birth weight, and duration of ventilator care. A total of 90 subjects completed the follow-up interviews. The mean gestational age at birth was 26.1±1.7 weeks, and the mean birth weight was 889.4±222.2 g. The incidence of RSVhospitalization in the study population was 8.9{\%} (8/90), and the mean hospital stay was 11.0±5.5 days, including one death. There were no statistically significant differences in the patients' demographic characteristics or risk factors for RSV hospitalization. When subgroup analyses were conducted, there were still no statistically significant differences. The administration of palivizumab prophylaxis during the entire RSV season is important in VLBWI with BPD, regardless of their gestational age and birth weight, or previous ventilator dependency.",
keywords = "Bronchopulmonary dysplasia, Hospitalization, Infant, Palivizumab, Preterm, Respiratory syncytial viruses",
author = "Han, {Young Mi} and Seo, {Hyun Joo} and Choi, {Seo Heui} and Jung, {Yu Jin} and Ahn, {So Yoon} and Yoo, {Hye Soo} and Sung, {Se In} and Shim, {Jae Won} and Lee, {Yeon Kyung} and Ko, {Sun Young} and Shin, {Son Moon} and Hwang, {Jong Hee} and Lee, {Jang Hoon} and Choi, {Byung Min} and Kim, {Eun Sun} and Jeon, {Ji Hyun} and Kim, {Sung Shin} and Chang, {Yun Sil} and Park, {Won Soon}",
year = "2015",
month = "1",
day = "1",
doi = "10.3346/jkms.2015.30.7.924",
language = "English",
volume = "30",
pages = "924--931",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "7",

}

TY - JOUR

T1 - Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia

AU - Han, Young Mi

AU - Seo, Hyun Joo

AU - Choi, Seo Heui

AU - Jung, Yu Jin

AU - Ahn, So Yoon

AU - Yoo, Hye Soo

AU - Sung, Se In

AU - Shim, Jae Won

AU - Lee, Yeon Kyung

AU - Ko, Sun Young

AU - Shin, Son Moon

AU - Hwang, Jong Hee

AU - Lee, Jang Hoon

AU - Choi, Byung Min

AU - Kim, Eun Sun

AU - Jeon, Ji Hyun

AU - Kim, Sung Shin

AU - Chang, Yun Sil

AU - Park, Won Soon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The aim of this study was to observe the effects of prophylactic palivizumab on hospitalization secondary to respiratory syncytial virus (RSV) infection (RSVhospitalization) in former very low birth weight infants (VLBWI) with bronchopulmonary dysplasia (BPD). This study also sought to identify the risk factors of RSVhospitalizationin this particular infant population. A prospective observational study was conducted between September 2007 and April 2008 in seven Korean hospitals. Children with a history of very low birth weight, a diagnosis of BPD and who were <2 yr old at the onset of the RSV season were included in this study. Palivizumab injections were administered monthly for a maximum of five months during the RSV season. RSVhospitalization rates were reviewed, and RSVhospitalization rates between subgroups were categorized by gestational age, birth weight, and duration of ventilator care. A total of 90 subjects completed the follow-up interviews. The mean gestational age at birth was 26.1±1.7 weeks, and the mean birth weight was 889.4±222.2 g. The incidence of RSVhospitalization in the study population was 8.9% (8/90), and the mean hospital stay was 11.0±5.5 days, including one death. There were no statistically significant differences in the patients' demographic characteristics or risk factors for RSV hospitalization. When subgroup analyses were conducted, there were still no statistically significant differences. The administration of palivizumab prophylaxis during the entire RSV season is important in VLBWI with BPD, regardless of their gestational age and birth weight, or previous ventilator dependency.

AB - The aim of this study was to observe the effects of prophylactic palivizumab on hospitalization secondary to respiratory syncytial virus (RSV) infection (RSVhospitalization) in former very low birth weight infants (VLBWI) with bronchopulmonary dysplasia (BPD). This study also sought to identify the risk factors of RSVhospitalizationin this particular infant population. A prospective observational study was conducted between September 2007 and April 2008 in seven Korean hospitals. Children with a history of very low birth weight, a diagnosis of BPD and who were <2 yr old at the onset of the RSV season were included in this study. Palivizumab injections were administered monthly for a maximum of five months during the RSV season. RSVhospitalization rates were reviewed, and RSVhospitalization rates between subgroups were categorized by gestational age, birth weight, and duration of ventilator care. A total of 90 subjects completed the follow-up interviews. The mean gestational age at birth was 26.1±1.7 weeks, and the mean birth weight was 889.4±222.2 g. The incidence of RSVhospitalization in the study population was 8.9% (8/90), and the mean hospital stay was 11.0±5.5 days, including one death. There were no statistically significant differences in the patients' demographic characteristics or risk factors for RSV hospitalization. When subgroup analyses were conducted, there were still no statistically significant differences. The administration of palivizumab prophylaxis during the entire RSV season is important in VLBWI with BPD, regardless of their gestational age and birth weight, or previous ventilator dependency.

KW - Bronchopulmonary dysplasia

KW - Hospitalization

KW - Infant

KW - Palivizumab

KW - Preterm

KW - Respiratory syncytial viruses

UR - http://www.scopus.com/inward/record.url?scp=84951772545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951772545&partnerID=8YFLogxK

U2 - 10.3346/jkms.2015.30.7.924

DO - 10.3346/jkms.2015.30.7.924

M3 - Article

C2 - 26130956

AN - SCOPUS:84951772545

VL - 30

SP - 924

EP - 931

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 7

ER -